Skip to main content
SpringerLink
Log in

The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Anorexia nervosa (AN) is a severe psychiatric disorder without approved medication intervention. Every class of psychoactive medication has been tried to improve treatment outcome; however, randomized controlled trials have been ambiguous at best and across studies have not shown robust improvements in weight gain and recovery. Here we review the available literature on pharmacological interventions since AN came to greater public recognition in the 1960s, including a critical review of why those trials may not have been successful. We further provide a neurobiological background for the disorder and discuss how cognition, learning, and emotion-regulating circuits could become treatment targets in the future. Making every effort to develop effective pharmacological treatment options for AN is imperative as it continues to be a complex psychiatric disorder with high disease burden and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaye WH, Wierenga CE, Bailer UF, Simmons AN, Bischoff-Grethe A. Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa. Trends Neurosci. 2013;36(2):110–20.

    Article  CAS  PubMed  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5™). Arlington: American Psychiatric Publishing; 2013.

    Google Scholar 

  3. Golden NH, Katzman DK, Kreipe RE, Stevens SL, Sawyer SM, Rees J, et al. Eating disorders in adolescents: position paper of the Society for Adolescent Medicine. J Adolesc Health. 2003;33(6):496–503.

    PubMed  Google Scholar 

  4. Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry. 1995;152(7):1073–4.

    Article  CAS  PubMed  Google Scholar 

  5. Fitzpatrick KK, Lock J. Anorexia nervosa. BMJ Clin Evid. 2011;2011:1011.

    PubMed  PubMed Central  Google Scholar 

  6. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348–58.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Brand-Gothelf A, Leor S, Apter A, Fennig S. The impact of comorbid depressive and anxiety disorders on severity of anorexia nervosa in adolescent girls. J Nerv Ment Dis. 2014;202(10):759–62.

    Article  PubMed  Google Scholar 

  8. Hughes EK, Goldschmidt AB, Labuschagne Z, Loeb KL, Sawyer SM, Le Grange D. Eating disorders with and without comorbid depression and anxiety: similarities and differences in a clinical sample of children and adolescents. Eur Eat Disord Rev. 2013;21(5):386–94.

    Article  PubMed  Google Scholar 

  9. Attia E. Anorexia nervosa: current status and future directions. Annu Rev Med. 2010;61:425–35.

    Article  CAS  PubMed  Google Scholar 

  10. Powers PS, Bruty H. Pharmacotherapy for eating disorders and obesity. Child Adolesc Psychiatr Clin N Am. 2009;18(1):175–87.

    Article  PubMed  Google Scholar 

  11. Monge MC, Forman SF, McKenzie NM, Rosen DS, Mammel KA, Callahan ST, et al. Use of psychopharmacologic medications in adolescents with restrictive eating disorders: analysis of data from the National Eating Disorder Quality Improvement Collaborative. J Adolesc Health. 2015;57(1):66–72.

    Article  PubMed  Google Scholar 

  12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.

    Article  PubMed  Google Scholar 

  13. Lavenstein AF, Dacaney EP, Lasagna L, Vanmetre TE. Effect of cyproheptadine on asthmatic children. Study of appetite, weight gain, and linear growth. JAMA. 1962;180:912–6.

    Article  CAS  PubMed  Google Scholar 

  14. Zubiate TN. Tratamiento de la anorexia nervosa con una associacian cyproheptadine-vitaminas. Revista Medica de la Caja Nacional de Segura Social. 1970;19:147–53.

    Google Scholar 

  15. Goldberg SC, Halmi KA, Eckert ED, Casper RC, Davis JM. Cyproheptadine in anorexia nervosa. Br J Psychiatry. 1979;134:67–70.

    Article  CAS  PubMed  Google Scholar 

  16. Goldberg SC, Eckert ED, Halmi KA, Casper RC, Davis JM, Roper M. Effects of cyproheptadine on symptoms and attitudes in anorexia nervosa. Arch Gen Psychiatry. 1980;37(9):1083.

    Article  CAS  PubMed  Google Scholar 

  17. Halmi KA, Eckert E, LaDu TJ, Cohen J. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986;43(2):177–81.

    Article  CAS  PubMed  Google Scholar 

  18. Biederman J, Herzog DB, Rivinus TM, Harper GP, Ferber RA, Rosenbaum JF, et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1985;5(1):10–6.

    Article  CAS  PubMed  Google Scholar 

  19. Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J. 1980;56(Suppl 1):79–85.

    PubMed  Google Scholar 

  20. Crisp AH, Lacey JH, Crutchfield M. Clomipramine and ‘drive’ in people with anorexia nervosa: an in-patient study. Br J Psychiatry. 1987;150:355–8.

    Article  CAS  PubMed  Google Scholar 

  21. Ruggiero G, Laini V, Mauri M, Ferrari V, Clemente A, Lugo F, et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(5):1049–59.

    Article  CAS  PubMed  Google Scholar 

  22. Strobel M, Warnke A, Roth M, Schulze U. Paroxetine versus clomipramine in female adolescents suffering from anorexia nervosa and depressive episode: a retrospective study on tolerability, reasons for discontinuing the antidepressive treatment and different outcome measurements. Z Kinder Jugendpsychiatr. 2004;32(4):279–89.

    Article  Google Scholar 

  23. Kennedy SH, Piran N, Garfinkel PE. Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid. J Clin Psychopharmacol. 1985;5(5):279–85.

    Article  CAS  PubMed  Google Scholar 

  24. Barry VC, Klawans HL. On the role of dopamine in the pathophysiology of anorexia nervosa. J Neural Transm. 1976;38(2):107–22.

    Article  CAS  PubMed  Google Scholar 

  25. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1982;66(6):445–50.

    Article  CAS  PubMed  Google Scholar 

  26. Weizman A, Tyano S, Wijsenbeek H, Ben David M. Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa. Psychother Psychosom. 1985;43(3):136–40.

    Article  CAS  PubMed  Google Scholar 

  27. Cassano G, Miniati M, Pini S, Rotondo A, Banti S, Borri C, et al. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Disord. 2003;33:172–7.

    Article  PubMed  Google Scholar 

  28. Mauri M, Miniati M, Mariani MG, Ciberti A, Dell’Osso L. Haloperidol for severe anorexia nervosa restricting type with delusional body image disturbance: a nine-case chart review. Eat Weight Disord. 2013;18(3):329–32.

    Article  PubMed  Google Scholar 

  29. Gross HA, Ebert MH, Faden VB, Goldberg SC, Nee LE, Kaye WH. A double-blind controlled trial of lithium carbonate primary anorexia nervosa. J Clin Psychopharmacol. 1981;1(6):376–81.

    Article  CAS  PubMed  Google Scholar 

  30. Bakan R. The role of zinc in anorexia nervosa: etiology and treatment. Med Hypotheses. 1979;5(7):731–6.

    Article  CAS  PubMed  Google Scholar 

  31. Bryce-Smith D, Simpson RI. Case of anorexia nervosa responding to zinc sulphate. Lancet. 1984;2(8398):350.

    Article  CAS  PubMed  Google Scholar 

  32. Katz RL, Keen CL, Litt IF, Hurley LS, Kellams-Harrison KM, Glader LJ. Zinc deficiency in anorexia nervosa. J Adolesc Health Care. 1987;8(5):400–6.

    Article  CAS  PubMed  Google Scholar 

  33. Safai-Kutti S. Oral zinc supplementation in anorexia nervosa. Acta Psychiatr Scand Suppl. 1990;361:14–7.

    Article  CAS  PubMed  Google Scholar 

  34. Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord. 1994;15(3):251–5.

    CAS  PubMed  Google Scholar 

  35. Lask B, Fosson A, Rolfe U, Thomas S. Zinc deficiency and childhood-onset anorexia nervosa. J Clin Psychiatry. 1993;54(2):63–6.

    CAS  PubMed  Google Scholar 

  36. Suzuki H, Asakawa A, Li JB, Tsai M, Amitani H, Ohinata K, et al. Zinc as an appetite stimulator: the possible role of zinc in the progression of diseases such as cachexia and sarcopenia. Recent Pat Food Nutr Agric. 2011;3(3):226–31.

    Article  CAS  PubMed  Google Scholar 

  37. Levenson CW. Zinc regulation of food intake: new insights on the role of neuropeptide Y. Nutr Rev. 2003;61(7):247–9.

    Article  PubMed  Google Scholar 

  38. Moore R, Mills IH, Forster A. Naloxone in the treatment of anorexia nervosa: effect on weight gain and lipolysis. J R Soc Med. 1981;74(2):129–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Marrazzi MA, Bacon JP, Kinzie J, Luby ED. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int Clin Psychopharmacol. 1995;10(3):163–72.

    Article  CAS  PubMed  Google Scholar 

  40. Gross H, Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED, et al. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol. 1983;3(3):165–71.

    Article  CAS  PubMed  Google Scholar 

  41. Andries A, Frystyk J, Flyvbjerg A, Stoving RK. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord. 2014;47(1):18–23.

    Article  PubMed  Google Scholar 

  42. Steinglass JE, Kaplan SC, Liu Y, Wang Y, Walsh BT. The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: a preliminary report. Int J Eat Disord. 2014;47(8):901–4.

    Article  PubMed  Google Scholar 

  43. Rieg TS, Aravich PF. Systemic clonidine increases feeding and wheel running but does not affect rate of weight loss in rats subjected to activity-based anorexia. Pharmacol Biochem Behav. 1994;47(2):215–8.

    Article  CAS  PubMed  Google Scholar 

  44. Casper RC, Schlemmer RFJ, Javaid JI. A placebo-controlled crossover study of oral clonidine in acute anorexia nervosa. Psychiatry Res. 1987;20(3):249–60.

    Article  CAS  PubMed  Google Scholar 

  45. Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry. 1990;51(9):378–82.

    CAS  PubMed  Google Scholar 

  46. Kaye WH, Weltzin TE, Hsu LK, Bulik CM. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry. 1991;52(11):464–71.

    CAS  PubMed  Google Scholar 

  47. Oliveros SC, Iruela LM, Caballero L, Baca E. Fluoxetine-induced anorexia in a bulimic patient. Am J Psychiatry. 1992;149(8):1113–4.

    CAS  PubMed  Google Scholar 

  48. Yu J, Stewart Agras W, Halmi KA, Crow S, Mitchell J, Bryson SW. A 1-year follow-up of a multi-center treatment trial of adults with anorexia nervosa. Eat Weight Disord. 2011;16(3):e177–81.

    Article  CAS  PubMed  Google Scholar 

  49. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry. 1998;155(4):548–51.

    Article  CAS  PubMed  Google Scholar 

  50. Strober M, Pataki C, Freeman R, DeAntonio M. No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study. J Child Adolesc Psychopharmacol. 1999;9(3):195–201.

    Article  CAS  PubMed  Google Scholar 

  51. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry. 2001;49(7):644–52.

    Article  CAS  PubMed  Google Scholar 

  52. Ruggiero GM, Mauri MC, Omboni AC, Volonteri LS, Dipasquale S, Malvini L, et al. Nutritional management of anorexic patients with and without fluoxetine: 1-year follow-up. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):425–30.

    Article  CAS  PubMed  Google Scholar 

  53. Strober M, Freeman R, DeAntonio M, Lampert C, Diamond J. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls. Psychopharmacol Bull. 1997;33(3):425–31.

    CAS  PubMed  Google Scholar 

  54. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006;295(22):2605–12.

    Article  CAS  PubMed  Google Scholar 

  55. Ricca V, Mannucci E, Paionni A, Di Bernardo M, Cellini M, Cabras PL, et al. Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eat Weight Disord. 1999;4(1):10–4.

    Article  CAS  PubMed  Google Scholar 

  56. Barbarich NC, McConaha CW, Halmi KA, Gendall K, Sunday SR, Gaskill J, et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int J Eat Disord. 2004;35(1):10–5.

    Article  PubMed  Google Scholar 

  57. Calandra C, Gulino V, Inserra L, Giuffrida A. The use of citalopram in an integrated approach to the treatment of eating disorders: an open study. Eat Weight Disord. 1999;4(4):207–10.

    Article  CAS  PubMed  Google Scholar 

  58. Fassino S, Leombruni P, Abbate Daga G, Brustolin A, Migliaretti G, Cavallo F, et al. Efficacy of citalopram in anorexia nervosa: a pilot study. Euro Neuropsychopharm. 2002;12:453–9.

    Article  CAS  Google Scholar 

  59. Pallanti S, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. Eat Weight Disord. 1997;2(4):216–21.

    Article  CAS  PubMed  Google Scholar 

  60. Santonastaso P, Friederici S, Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol. 2001;11(2):143–50.

    Article  CAS  PubMed  Google Scholar 

  61. Holtkamp K, Konrad K, Kaiser N, Ploenes Y, Heussen N, Grzella I, et al. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res. 2004;39:303–10.

    Article  Google Scholar 

  62. Ferguson CP, La Via MC, Crossan PJ, Kaye WH. Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord. 1999;25(1):11–7.

    Article  CAS  PubMed  Google Scholar 

  63. Hrdlicka M, Beranova I, Zamecnikova R, Urbanek T. Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study. Eur Child Adolesc Psychiatry. 2008;17(3):187–9.

    Article  PubMed  Google Scholar 

  64. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double- blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144:288–92.

    Article  CAS  PubMed  Google Scholar 

  65. Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord. 2002;32:146–54.

    Article  PubMed  Google Scholar 

  66. Barbarich N, McConaha C, Gaskill J, LaVia M, Frank GK, Brooks S, et al. An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry. 2004;65:1480–2.

    Article  CAS  PubMed  Google Scholar 

  67. Malina A, Gaskill J, McConaha C, Frank GK, LaVia M, Scholar L, et al. Olanzapine treatment of anorexia nervosa: a restrospective study. Int J Eat Disord. 2003;33(2):234–7.

    Article  PubMed  Google Scholar 

  68. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry. 2005;13(1):72–5.

    Article  PubMed  Google Scholar 

  69. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22(4):197–204.

    Article  PubMed  Google Scholar 

  70. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165(10):1281–8.

    Article  PubMed  Google Scholar 

  71. Leggero C, Masi G, Brunori E, Calderoni S, Carissimo R, Maestro S, et al. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol. 2010;20(2):127–33.

    Article  PubMed  Google Scholar 

  72. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177–82.

    Article  CAS  PubMed  Google Scholar 

  73. Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):207–12.

    Article  CAS  PubMed  Google Scholar 

  74. Norris ML, Spettigue W, Buchholz A, Henderson KA, Gomez R, Maras D, et al. Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):213–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 2007;32(4):402–6.

    Article  CAS  PubMed  Google Scholar 

  76. Yasuhara D, Nakahara T, Harada T, Inui A. Olanzapine-induced hyperglycemia in anorexia nervosa. Am J Psychiatry. 2007;164(3):528–9.

    Article  PubMed  Google Scholar 

  77. Bosanac P, Kurlender S, Norman T, Hallam K, Wesnes K, Manktelow T, et al. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol. 2007;22(4):223–30.

    Article  CAS  PubMed  Google Scholar 

  78. Powers PS, Bannon Y, Eubanks R, McCormick T. Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int J Eat Disord. 2007;40(1):21–6.

    Article  PubMed  Google Scholar 

  79. Powers PS, Klabunde M, Kaye W. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev. 2012;20(4):331–4.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Court A, Mulder C, Kerr M, Yuen HP, Boasman M, Goldstone S, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res. 2010;44(15):1027–34.

    Article  PubMed  Google Scholar 

  81. Kracke EJ, Tosh AK. Treatment of anorexia nervosa with long-term risperidone in an outpatient setting: case study. Springerplus. 2014;3:706.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Newman-Toker J. Risperidone in anorexia nervosa. J Am Acad Child Adolesc Psychiatry. 2000;39(8):941–2.

    Article  CAS  PubMed  Google Scholar 

  83. Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011;50(9):915–24.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Trunko ME, Schwartz TA, Duvvuri V, Kaye WH. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord. 2011;44(3):269–75.

    Article  PubMed  Google Scholar 

  85. Frank GK. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa: a case series. Int J Eat Disord. 2015;. doi:10.1002/eat.22485 (Epub 23 Nov 2015).

    PubMed  Google Scholar 

  86. Frank GK. Could dopamine agonists aid in drug development for anorexia nervosa? Front Nutr. 2014;1:19.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Otto MW, Kredlow MA, Smits JA, Hofmann SG, Tolin DF, de Kleine RA, van Minnen A, Evins AE, Pollack MH. Enhancement of Psychosocial Treatment With d-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry. 2015. doi:10.1016/j.biopsych.2015.09.007.

    PubMed  Google Scholar 

  88. Steinglass J, Sysko R, Schebendach J, Broft A, Strober M, Walsh BT. The application of exposure therapy and d-cycloserine to the treatment of anorexia nervosa: a preliminary trial. J Psychiatr Pract. 2007;13(4):238–45.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Levinson CA, Rodebaugh TL, Fewell L, Kass AE, Riley EN, Stark L, et al. d-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry. 2015;76(6):e787–93.

    Article  PubMed  Google Scholar 

  90. Lechin F, van der Dijs B, Pardey-Maldonado B, Baez S, Lechin ME. Anorexia nervosa versus hyperinsulinism: therapeutic effects of neuropharmacological manipulation. Ther Clin Risk Manag. 2011;7:53–8.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Bloch M, Ish-Shalom S, Greenman Y, Klein E, Latzer Y. Dehydroepiandrosterone treatment effects on weight, bone density, bone metabolism and mood in women suffering from anorexia nervosa-a pilot study. Psychiatry Res. 2012;200(2–3):544–9.

    Article  CAS  PubMed  Google Scholar 

  92. Hotta M, Ohwada R, Akamizu T, Shibasaki T, Takano K, Kangawa K. Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. Endocr J. 2009;56(9):1119–28.

    Article  CAS  PubMed  Google Scholar 

  93. Okita K, Shiina A, Nakazato M, Iyo M. Tandospirone, a 5-HT1A partial agonist is effective in treating anorexia nervosa: a case series. Ann Gen Psychiatry. 2013;12(1):7.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Misra M, Katzman DK, Estella NM, Eddy KT, Weigel T, Goldstein MA, et al. Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial. J Clin Psychiatry. 2013;74(8):e765–71.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab. 1995;80(3):898–904.

    CAS  PubMed  Google Scholar 

  96. Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab. 2005;90(3):1428–33.

    Article  CAS  PubMed  Google Scholar 

  97. Hill K, Bucuvalas J, McClain C, Kryscio R, Martini RT, Alfaro MP, et al. Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J Child Adolesc Psychopharmacol. 2000;10(1):3–8.

    Article  CAS  PubMed  Google Scholar 

  98. Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. The role of “mixed” orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa. Int J Endocrinol. 2013;2013:483145.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Van den Eynde F, Suda M, Broadbent H, Guillaume S, Van den Eynde M, Steiger H, et al. Structural magnetic resonance imaging in eating disorders: a systematic review of voxel-based morphometry studies. Eur Eat Disord Rev. 2012;20(2):94–105.

    Article  PubMed  Google Scholar 

  100. King JA, Geisler D, Ritschel F, Boehm I, Seidel M, Roschinski B, et al. Global cortical thinning in acute anorexia nervosa normalizes following long-term weight restoration. Biol Psychiatry. 2015;77(7):624–32.

    Article  PubMed  Google Scholar 

  101. Frank GK, Shott ME, Hagman JO, Mittal VA. Alterations in brain structures related to taste reward circuitry in ill and recovered anorexia nervosa and in bulimia nervosa. Am J Psychiatry. 2013;170(10):1152–60.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Frank GK, Shott ME, Hagman JO, Yang TT. Localized brain volume and white matter integrity alterations in adolescent anorexia nervosa. J Am Acad Child Adolesc Psychiatry. 2013;52(10):1066–1075 e5.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Rolls ET. Information processing in the taste system of primates. J Exp Biol. 1989;146:141–64.

    CAS  PubMed  Google Scholar 

  104. Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC, et al. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biol Psychiatry. 2005;58(11):908–12.

    Article  CAS  PubMed  Google Scholar 

  105. Gerard N, Pieters G, Goffin K, Bormans G, Van Laere K. Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry. 2011;70(8):777–84.

    Article  CAS  PubMed  Google Scholar 

  106. Berridge KC. ‘Liking’ and ‘wanting’ food rewards: brain substrates and roles in eating disorders. Physiol Behav. 2009;97(5):537–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci. 2002;22(9):3306–11.

    CAS  PubMed  Google Scholar 

  108. Frank GK. Reward and neurocomputational processes. Curr Top Behav Neurosci. 2011;6:95–110.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Frank GK. Advances from neuroimaging studies in eating disorders. CNS Spectr. 2015;20(4):391–400. doi:10.1017/S1092852915000012.

    Article  PubMed  Google Scholar 

  110. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1–27.

    CAS  PubMed  Google Scholar 

  111. Yilmaz Z, Kaplan AS, Tiwari AK, Levitan RD, Piran S, Bergen AW, et al. The role of leptin, melanocortin, and neurotrophin system genes on body weight in anorexia nervosa and bulimia nervosa. J Psychiatr Res. 2014;55:77–86.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Boraska V, Franklin CS, Floyd JA, Thornton LM, Huckins LM, Southam L, et al. A genome-wide association study of anorexia nervosa. Mol Psychiatry. 2014;19(10):1085–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ, et al. A genome-wide association study on common SNPs and rare CNVs in anorexia nervosa. Mol Psychiatry. 2011;16(9):949–59.

    Article  CAS  PubMed  Google Scholar 

  114. Brandys MK, de Kovel CG, Kas MJ, van Elburg AA, Adan RA. Overview of genetic research in anorexia nervosa: the past, the present and the future. Int J Eat Disord. 2015;48(7):814–25.

    Article  PubMed  Google Scholar 

  115. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics Consortium, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Gutierrez E. A rat in the labyrinth of anorexia nervosa: contributions of the activity-based anorexia rodent model to the understanding of anorexia nervosa. Int J Eat Disord. 2013;46(4):289–301.

    Article  PubMed  Google Scholar 

  117. Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry. 2005;58(8):651–7.

    Article  CAS  PubMed  Google Scholar 

  118. Klenotich SJ, Seiglie MP, McMurray MS, Roitman JD, Le Grange D, Dugad P, et al. Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice. Neuropsychopharmacology. 2012;37(7):1620–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Verhagen LA, Luijendijk MC, Hillebrand JJ, Adan RA. Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa. Eur Neuropsychopharmacol. 2009;19(3):153–60.

    Article  CAS  PubMed  Google Scholar 

  120. Atchley DP, Eckel LA. Fenfluramine treatment in female rats accelerates the weight loss associated with activity-based anorexia. Pharmacol Biochem Behav. 2005;80(2):273–9.

    Article  CAS  PubMed  Google Scholar 

  121. Hillebrand JJ, Heinsbroek AC, Kas MJ, Adan RA. The appetite suppressant d-fenfluramine reduces water intake, but not food intake, in activity-based anorexia. J Mol Endocrinol. 2006;36(1):153–62.

    Article  CAS  PubMed  Google Scholar 

  122. Atchley DP, Eckel LA. Treatment with 8-OH-DPAT attenuates the weight loss associated with activity-based anorexia in female rats. Pharmacol Biochem Behav. 2006;83(4):547–53.

    Article  CAS  PubMed  Google Scholar 

  123. Verty AN, Evetts MJ, Crouch GJ, McGregor IS, Stefanidis A, Oldfield BJ. The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology. 2011;36(7):1349–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Lewis DY, Brett RR. Activity-based anorexia in C57/BL6 mice: effects of the phytocannabinoid, Delta9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2. Eur Neuropsychopharmacol. 2010;20(9):622–31.

    Article  CAS  PubMed  Google Scholar 

  125. Verhagen LA, Luijendijk MC, Adan RA. Leptin reduces hyperactivity in an animal model for anorexia nervosa via the ventral tegmental area. Eur Neuropsychopharmacol. 2011;21(3):274–81.

    Article  CAS  PubMed  Google Scholar 

  126. Exner C, Hebebrand J, Remschmidt H, Wewetzer C, Ziegler A, Herpertz S, et al. Leptin suppresses semi-starvation induced hyperactivity in rats: implications for anorexia nervosa. Mol Psychiatry. 2000;5(5):476–81.

    Article  CAS  PubMed  Google Scholar 

  127. Brown AJ, Avena NM, Hoebel BG. A high-fat diet prevents and reverses the development of activity-based anorexia in rats. Int J Eat Disord. 2008;41(5):383–9.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Gile E, Hagman J, Pan Z, MacLean P, Higgins J. Weight restoration on a high carbohydrate refeeding diet promotes rapid weight regain and hepatic lipid accumulation in female anorexic rats. Nutr Metab. 2016;13(18):11.

    Google Scholar 

  129. Taksande BG, Chopde CT, Umekar MJ, Kotagale NR. Agmatine attenuates hyperactivity and weight loss associated with activity-based anorexia in female rats. Pharmacol Biochem Behav. 2015;132:136–41.

    Article  CAS  PubMed  Google Scholar 

  130. Wable GS, Chen YW, Rashid S, Aoki C. Exogenous progesterone exacerbates running response of adolescent female mice to repeated food restriction stress by changing alpha4-GABAA receptor activity of hippocampal pyramidal cells. Neuroscience. 2015;310:322–41.

    Article  CAS  PubMed  Google Scholar 

  131. Baker JH, Girdler SS, Bulik CM. The role of reproductive hormones in the development and maintenance of eating disorders. Expert Rev Obstet Gynecol. 2012;7(6):573–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Frank GK, Reynolds JR, Shott ME, Jappe L, Yang TT, Tregellas JR, et al. Anorexia nervosa and obesity are associated with opposite brain reward response. Neuropsychopharmacology. 2012;37(9):2031–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Klenotich SJ, Ho EV, McMurray MS, Server CH, Dulawa SC. Dopamine D2/3 receptor antagonism reduces activity-based anorexia. Transl Psychiatry. 2015;5:e613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Mequinion M, Chauveau C, Viltart O. The use of animal models to decipher physiological and neurobiological alterations of anorexia nervosa patients. Front Endocrinol (Lausanne). 2015;6:68.

    PubMed  PubMed Central  Google Scholar 

  135. Diane A, Vine DF, Russell JC, Heth CD, Pierce WD, Proctor SD. Interrelationship of CB1R and OBR pathways in regulation of metabolic, neuroendocrine, and behavioral responses to food restriction and voluntary wheel running. J Appl Physiol (1985). 2014;117(2):97–104.

    Article  CAS  PubMed Central  Google Scholar 

  136. McOmish CE, Burrows EL, Hannan AJ. Identifying novel interventional strategies for psychiatric disorders: integrating genomics, ‘enviromics’ and gene-environment interactions in valid preclinical models. Br J Pharmacol. 2014;171(20):4719–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Guarda AS, Schreyer CC, Boersma GJ, Tamashiro KL, Moran TH. Anorexia nervosa as a motivated behavior: Relevance of anxiety, stress, fear and learning. Physiol Behav. 2015;152(Pt B):466–72.

    Article  CAS  PubMed  Google Scholar 

  138. Yardley MM, Ray LA. Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. Addict Biol. 2016. doi:10.1111/adb.12349.

    PubMed  Google Scholar 

  139. Poldrack RA, Farah MJ. Progress and challenges in probing the human brain. Nature. 2015;526(7573):371–9.

    Article  CAS  PubMed  Google Scholar 

  140. Avena NM, Rada P, Hoebel BG. Underweight rats have enhanced dopamine release and blunted acetylcholine response in the nucleus accumbens while bingeing on sucrose. Neuroscience. 2008;156(4):865–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Carr KD. Chronic food restriction: enhancing effects on drug reward and striatal cell signaling. Physiol Behav. 2007;91(5):459–72.

    Article  CAS  PubMed  Google Scholar 

  142. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010;13(5):635–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Ban TA. The role of serendipity in drug discovery. Dialogues Clin Neurosci. 2006;8(3):335–44.

    PubMed  PubMed Central  Google Scholar 

  144. Stahl SM. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx. 2006;3(1):3–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Rey CD, Lipps J, Shansky RM. Dopamine D1 receptor activation rescues extinction impairments in low-estrogen female rats and induces cortical layer-specific activation changes in prefrontal-amygdala circuits. Neuropsychopharmacology. 2014;39(5):1282–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. de Souza Caetano KA, de Oliveira AR, Brandao ML. Dopamine D2 receptors modulate the expression of contextual conditioned fear: role of the ventral tegmental area and the basolateral amygdala. Behav Pharmacol. 2013;24(4):264–74.

  147. de Oliveira AR, Reimer AE, Brandao ML. Dopamine D2 receptor mechanisms in the expression of conditioned fear. Pharmacol Biochem Behav. 2006;84(1):102–11.

    Article  PubMed  CAS  Google Scholar 

  148. Nader K, LeDoux J. The dopaminergic modulation of fear: quinpirole impairs the recall of emotional memories in rats. Behav Neurosci. 1999;113(1):152–65.

    Article  CAS  PubMed  Google Scholar 

  149. Ponnusamy R, Nissim HA, Barad M. Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem. 2005;12(4):399–406.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 8th ed. Oxford: Oxford University Press; 2003.

    Google Scholar 

  151. Braun AR, Laruelle M, Mouradian MM. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J Neural Transm. 1997;104(4–5):341–62.

    Article  CAS  PubMed  Google Scholar 

  152. Biojone C, Casarotto PC, Resstel LB, Zangrossi H Jr, Guimaraes FS, Moreira FA. Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. J Psychopharmacol. 2011;25(6):801–7.

    Article  CAS  PubMed  Google Scholar 

  153. Kelley AE, Schiltz CA, Landry CF. Neural systems recruited by drug- and food-related cues: studies of gene activation in corticolimbic regions. Physiol Behav. 2005;86(1–2):11–4.

    Article  CAS  PubMed  Google Scholar 

  154. Dignon A, Beardsmore A, Spain S, Kuan A. ‘Why I won’t eat’: patient testimony from 15 anorexics concerning the causes of their disorder. J Health Psychol. 2006;11(6):942–56.

    Article  PubMed  Google Scholar 

  155. Thaler L, Israel M, Antunes JM, Sarin S, Zuroff DC, Steiger H. An examination of the role of autonomous versus controlled motivation in predicting inpatient treatment outcome for anorexia nervosa. Int J Eat Disord. 2016. doi:10.1002/eat.22510.

    PubMed  Google Scholar 

  156. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36(2):241–63.

    Article  CAS  PubMed  Google Scholar 

  157. Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, Vernier P. Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell. 2003;95(7):489–502.

    Article  CAS  PubMed  Google Scholar 

  158. Barton AC, Black LE, Sibley DR. Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. Mol Pharmacol. 1991;39(5):650–8.

    CAS  PubMed  Google Scholar 

  159. Jiang D, Sibley DR. Regulation of D(1) dopamine receptors with mutations of protein kinase phosphorylation sites: attenuation of the rate of agonist-induced desensitization. Mol Pharmacol. 1999;56(4):675–83.

    CAS  PubMed  Google Scholar 

  160. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, Caron MG. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem. 2001;276(40):37409–14.

    Article  CAS  PubMed  Google Scholar 

  161. Lamey M, Thompson M, Varghese G, Chi H, Sawzdargo M, George SR, et al. Distinct residues in the carboxyl tail mediate agonist-induced desensitization and internalization of the human dopamine D1 receptor. J Biol Chem. 2002;277(11):9415–21.

    Article  CAS  PubMed  Google Scholar 

  162. Johanson AJ, Knorr NJ. Letter: Treatment of anorexia nervosa by levodopa. Lancet. 1974;2(7880):591.

    Article  CAS  PubMed  Google Scholar 

  163. Zucker NL, Losh M, Bulik CM, LaBar KS, Piven J, Pelphrey KA. Anorexia nervosa and autism spectrum disorders: guided investigation of social cognitive endophenotypes. Psychol Bull. 2007;133(6):976–1006.

    Article  PubMed  Google Scholar 

  164. Treasure J, Corfield F, Cardi V. A three-phase model of the social emotional functioning in eating disorders. Eur Eat Disord Rev. 2012;20(6):431–8.

    Article  PubMed  Google Scholar 

  165. Monteleone AM, Scognamiglio P, Volpe U, Di Maso V, Monteleone P. Investigation of oxytocin secretion in anorexia nervosa and bulimia nervosa: relationships to temperament personality dimensions. Eur Eat Disord Rev. 2016;24(1):52–6.

    Article  PubMed  Google Scholar 

  166. Lawson EA, Holsen LM, Santin M, Meenaghan E, Eddy KT, Becker AE, et al. Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa. J Clin Endocrinol Metab. 2012;97(10):E1898–908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Lawson EA, Holsen LM, Santin M, DeSanti R, Meenaghan E, Eddy KT, et al. Postprandial oxytocin secretion is associated with severity of anxiety and depressive symptoms in anorexia nervosa. J Clin Psychiatry. 2013;74(5):e451–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Kim YR, Eom JS, Yang JW, Kang J, Treasure J. The impact of oxytocin on food intake and emotion recognition in patients with eating disorders: a double blind single dose within-subject cross-over design. PLoS One. 2015;10(9):e0137514.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  169. Kim YR, Oh SM, Corfield F, Jeong DW, Jang EY, Treasure J. Intranasal oxytocin lessens the attentional bias to adult negative faces: a double blind within-subject experiment. Psychiatry Investig. 2014;11(2):160–6.

    Article  PubMed  PubMed Central  Google Scholar 

  170. Kim YR, Kim CH, Cardi V, Eom JS, Seong Y, Treasure J. Intranasal oxytocin attenuates attentional bias for eating and fat shape stimuli in patients with anorexia nervosa. Psychoneuroendocrinology. 2014;44:133–42.

    Article  CAS  PubMed  Google Scholar 

  171. Hyman SE. Psychiatric drug development: diagnosing a crisis. Cerebrum. 2013;2013:5.

    PubMed  PubMed Central  Google Scholar 

  172. Weinberger DR. New directions in psychiatric therapeutics. NeuroRx. 2006;3(1):1–2.

    Article  PubMed  PubMed Central  Google Scholar 

  173. Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry. 2015;20(10):1142–50.

    Article  CAS  PubMed  Google Scholar 

  174. Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother. 2015;16(11):1669–81.

    Article  CAS  PubMed  Google Scholar 

  175. Perna G, Schruers K, Alciati A, Caldirola D. Novel investigational therapeutics for panic disorder. Expert Opin Investig Drugs. 2015;24(4):491–505.

    Article  CAS  PubMed  Google Scholar 

  176. Vadnie CA, Park JH, Abdel Gawad N, Ho AM, Hinton DJ, Choi DS. Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders. Front Neurosci. 2014;8:288.

    Article  PubMed  PubMed Central  Google Scholar 

  177. Bailer UF, Kaye WH. A review of neuropeptide and neuroendocrine dysregulation in anorexia and bulimia nervosa. Curr Drug Targets CNS Neurol Disord. 2003;2(1):53–9.

    Article  CAS  PubMed  Google Scholar 

  178. Kleiman SC, Watson HJ, Bulik-Sullivan EC, Huh EY, Tarantino LM, Bulik CM, et al. The intestinal microbiota in acute anorexia nervosa and during renourishment: relationship to depression, anxiety, and eating disorder psychopathology. Psychosom Med. 2015;77(9):969–81.

    Article  PubMed  Google Scholar 

  179. Jarvis S, Schultz SR. Prospects for optogenetic augmentation of brain function. Front Syst Neurosci. 2015;9:157.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Aleman A. Use of repetitive transcranial magnetic stimulation for treatment in psychiatry. Clin Psychopharmacol Neurosci. 2013;11(2):53–9.

    Article  PubMed  PubMed Central  Google Scholar 

  181. Kuo MF, Paulus W, Nitsche MA. Therapeutic effects of non-invasive brain stimulation with direct currents (tDCS) in neuropsychiatric diseases. Neuroimage. 2014;85(Pt 3):948–60.

    Article  PubMed  Google Scholar 

  182. Fitzgerald PB, Segrave RA. Deep brain stimulation in mental health: review of evidence for clinical efficacy. Aust N Z J Psychiatry. 2015;49(11):979–93.

    Article  PubMed  Google Scholar 

  183. Post A, Keck ME. Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms? J Psychiatr Res. 2001;35(4):193–215.

    Article  CAS  PubMed  Google Scholar 

  184. Nitsche MA, Kuo MF, Karrasch R, Wachter B, Liebetanz D, Paulus W. Serotonin affects transcranial direct current-induced neuroplasticity in humans. Biol Psychiatry. 2009;66(5):503–8.

    Article  CAS  PubMed  Google Scholar 

  185. Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2015;11:CD004692.

    PubMed  Google Scholar 

  186. Avraham Y, Saidian M, Burston JJ, Mevorach R, Vorobiev L, Magen I, et al. Fish oil promotes survival and protects against cognitive decline in severely undernourished mice by normalizing satiety signals. J Nutr Biochem. 2011;22(8):766–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Ayton AK, Azaz A, Horrobin DF. Rapid improvement of severe anorexia nervosa during treatment with ethyl-eicosapentaenoate and micronutrients. Eur Psychiatry. 2004;19(5):317–9.

    Article  PubMed  Google Scholar 

  188. Ayton AK, Azaz A, Horrobin DF. A pilot open case series of ethyl-EPA supplementation in the treatment of anorexia nervosa. Prostaglandins Leukot Essent Fatty Acids. 2004;71(4):205–9.

    Article  CAS  PubMed  Google Scholar 

  189. Yehuda S, Rabinovitz S. The Role of Essential Fatty Acids in Anorexia Nervosa and in Obesity. Crit Rev Food Sci Nutr. 2015. doi:10.1080/10408398.2013.809690.

  190. Vall E, Wade TD. Predictors of treatment outcome in individuals with eating disorders: a systematic review and meta-analysis. Int J Eat Disord. 2015;48(7):946–71.

    Article  PubMed  Google Scholar 

  191. Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015;351:h4320.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Psychiatry and Neuroscience, and Developmental Brain Research Program, University of Colorado Anschutz Medical Campus, Children’s Hospital Colorado, Gary Pavilion A036/B-130, 13123 East 16th Avenue, Aurora, CO, 80045, USA

    Guido K. W. Frank & Megan E. Shott

  2. School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

    Guido K. W. Frank

Authors
  1. Guido K. W. Frank
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megan E. Shott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido K. W. Frank.

Ethics declarations

Conflict of interest

Dr. Frank and Ms. Shott report no competing interests.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frank, G.K.W., Shott, M.E. The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects. CNS Drugs 30, 419–442 (2016). https://doi.org/10.1007/s40263-016-0335-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-016-0335-6

Keywords

Search

Navigation